Der Stellenwert von Bisphosphonaten in der Therapie des Prostatakarzinoms

Skeletal complications of bone metastases or secondary osteoporosis are a frequent event in patients with prostate cancer. Bisphosphonates have been widely used for both indications because of their capacity to prevent bone loss, to reduce pain and to inhibit metastatic growth. Possible side effects include acute phase reactions, osteonecrosis of the jaw and renal impairment. Therefore, the risks and benefits of therapy should be considered and informed consent obtained from the patient. Given current evidence the guidelines only allow a recommendation for use in patients with metastatic prostate cancer.